Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | MET | P08581 | 9/20 | 0.51 |
| ▸ | RIPK3 | Q9Y572 | 6/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MST1R | Q04912 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23749275 | 0.93 | KDR (0.53) | RETKDRMETRIPK3RIPK1 | |
| SCHEMBL23749417 | 0.91 | KDR (0.51) | RETKDRMETRIPK3RIPK1 | |
| SCHEMBL23749440 | 0.90 | RET (0.59) | RETKDRMETMST1RAXL | |
| SCHEMBL23771069 | 0.89 | KDR (0.54) | RETKDRMETRIPK3RIPK1 | |
| SCHEMBL23749307 | 0.89 | KDR (0.54) | RETKDRMETRIPK3RIPK1 | |
| SCHEMBL23771036 | 0.88 | RET (0.55) | RETKDRMETRIPK3RIPK1 | |
| SCHEMBL23749435 | 0.88 | KDR (0.69) | RETKDRMETRIPK3RIPK1 | |
| SCHEMBL23749360 | 0.88 | KDR (0.62) | RETKDRMETRIPK3RIPK1 | |
| SCHEMBL23749329 | 0.87 | MST1R (0.60) | RETKDRMETMST1RAXL | |
| SCHEMBL23749362 | 0.87 | RET (0.47) | RETKDRMETRIPK3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-01-21 | — | — | US | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | MERTK, AXL, TYRO3 | RET 4/4885KDR 10/4885MET 14/4885 |
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | MERTK, AXL, TYRO3 | RET 4/4885KDR 8/4885MET 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.